Diabetes Treatment and Patient Follow-Up in Türkiye: International Guide
- 26 Aug 2026
Diabetes Treatment and Patient Follow-Up in Türkiye
Diabetes is a chronic, multidimensional condition. Good care does not focus on HbA1c alone; it considers hypoglycaemia, daily glucose patterns, food, movement, sleep, weight, blood pressure, lipids, kidney function, eye and foot health, emotional wellbeing and access to treatment. The World Health Organization diabetes fact sheet notes that regular screening and treatment of complications can prevent or delay harmful outcomes.
Clinicly Medical Tourism can help an international patient transfer records to an appropriate endocrinology, internal-medicine or multidisciplinary team and coordinate facility communication, interpreting, travel and follow-up. Diagnosis, prescriptions and treatment changes remain the responsibility of an authorised clinician. Clinicly does not replace medical consultation or an independent second opinion.
Emergency warning: Confusion, seizure, loss of consciousness or inability to swallow safely during severe hypoglycaemia is an emergency. A trained person may use available glucagon according to its instructions; never give food or drink by mouth to an unconscious person, and call 112 in Türkiye. Marked thirst, frequent urination, vomiting, abdominal pain, deep/rapid breathing, fruity breath, profound drowsiness or confusion may indicate diabetic ketoacidosis or a hyperosmolar crisis. Attend an emergency department. The NHS describes DKA as requiring urgent hospital treatment, while the ADA classifies severe hypoglycaemia as an emergency.
Correctly classifying diabetes
| Condition | Core feature | Why classification matters |
|---|---|---|
| Type 1 diabetes | Very little or no endogenous insulin; onset at any age | Insulin is essential for survival; stopping it can cause ketoacidosis |
| Type 2 diabetes | Insulin resistance with progressive loss of insulin secretion | Lifestyle, several medicine classes and sometimes insulin are combined |
| Prediabetes | Glucose above normal but below the diabetes range | Weight, movement, sleep and risk management may delay progression |
| Gestational diabetes | Hyperglycaemia identified in pregnancy | Maternal-fetal monitoring and postpartum retesting are required |
| Other forms | Pancreatic disease, medicines such as steroids, monogenic or endocrine causes | Cause-specific treatment or family testing may be needed |
Adult age or higher body weight does not exclude type 1 diabetes. Unexpected weight loss, ketosis, rapid need for insulin, diabetes across generations at a young age or pancreatic disease may prompt selected use of C-peptide, autoantibodies, genetics or imaging.
Diagnostic tests and the limits of HbA1c
Diagnosis should use validated laboratory methods and clinical context. Unless there is unequivocal hyperglycaemia with classic symptoms or crisis, an abnormal result is generally confirmed on another day.
| Test | Common diagnostic threshold* | Important qualification |
| HbA1c | ≥6.5% | Reflects roughly three months; unreliable in some conditions |
| Fasting plasma glucose | ≥126 mg/dL (7.0 mmol/L) | Requires at least eight hours without caloric intake |
| 75-g OGTT, two-hour glucose | ≥200 mg/dL (11.1 mmol/L) | Preparation and sample timing matter |
| Random plasma glucose | ≥200 mg/dL (11.1 mmol/L) | Diagnostic with classic symptoms or hyperglycaemic crisis |
*Thresholds are educational; a clinician confirms the diagnosis. Gestational diabetes uses different tests and cut-offs.
Anaemia, haemoglobin variants, recent blood loss or transfusion, pregnancy, advanced kidney or liver disease and altered red-cell lifespan can distort HbA1c. It also hides sudden highs and lows. The NIDDK explanation of A1C highlights these limitations when glucose readings and HbA1c do not match. Type 1 or gestational diabetes should not be excluded by HbA1c alone.
The first comprehensive assessment
-
Confirm likely type, duration, previous crises, hypoglycaemia awareness and access to treatment.
-
Review medicines, insulin doses, injection sites, pump/CGM reports, supplements and allergies.
-
Plan HbA1c and relevant glucose measures; creatinine-eGFR and urine albumin-to-creatinine ratio; lipids and selected liver tests.
-
Assess blood pressure, weight, waist, diet, activity, smoking, alcohol, sleep apnoea, mental health and reproductive plans.
-
Arrange retinal, foot/neuropathy, dental and vaccination review according to diabetes type, duration and earlier results.
Individualised treatment
Type 1 diabetes
Basal-bolus insulin or a suitable pump, carbohydrate counting, correction factors, exercise planning and sick-day education form one system. Continuous glucose monitoring (CGM) shows trends and alarms; automated insulin-delivery systems may reduce burden and hypoglycaemia for some patients. Buying technology without education, consumables and sustainable support is not enough.
A person with type 1 diabetes must not stop basal insulin simply because they cannot eat. Fever, vomiting or high glucose may require ketone testing and the person’s written sick-day plan. People at risk of severe hypoglycaemia should have in-date glucagon and train family or companions to use it.
Type 2 diabetes
Treatment is selected according to atherosclerotic cardiovascular disease, heart failure, chronic kidney disease, weight priorities, hypoglycaemia risk, age, pregnancy potential, adverse effects, cost and access at home. Metformin, SGLT2 inhibitors, GLP-1 receptor agonists or dual GIP/GLP-1 medicines, DPP-4 inhibitors, sulfonylureas, thiazolidinediones and insulin have different benefit-risk profiles. A drug is not chosen solely by how strongly it lowers glucose.
SGLT2 inhibitors can be associated with ketoacidosis even when glucose is not dramatically high in some people. The medication plan around surgery, prolonged fasting or acute illness should be written by the treating team. Injectable weight/diabetes medicines can affect gastric emptying; do not stop or continue them on your own before sedation—coordinate with the prescriber and anaesthesia team. Herbal “sugar cures” do not replace treatment and may interact with medicines.
Nutrition, activity and self-management education
There is no single diabetes diet. A registered dietitian should adapt the plan to culture, kidney function, medicines, weight and hypoglycaemia risk. Less processed, fibre-rich foods, appropriate portions and a workable meal pattern may help. Exercise advice must account for heart disease, foot ulcers, retinopathy and medication effects. Diabetes self-management education should cover monitoring, injections, low-glucose treatment, sick days and foot care.
Weight management and metabolic surgery
Behavioural support, medicines or metabolic surgery in selected people can improve weight and metabolic control in type 2 diabetes. Surgery is not a guaranteed cure. Remission may occur, but diabetes can return; lifelong nutritional, micronutrient, surgical and diabetes follow-up is required. Eligibility should be evaluated by endocrinology, metabolic surgery, dietetics and, when appropriate, psychology.
Pregnancy and diabetes
Preconception counselling should address glucose targets, medication safety, folate and eye/kidney assessment. Some glucose, blood-pressure and lipid medicines are unsuitable in pregnancy. Gestational diabetes requires obstetric-endocrine collaboration, postpartum testing and later surveillance because future type 2 diabetes risk remains increased.
Why targets differ between people
HbA1c, pre/post-meal glucose, CGM time in range and hypoglycaemia limits must be individualised. Pregnancy, childhood, older age, kidney disease, cardiovascular disease, severe or unrecognised hypoglycaemia and life expectancy all change the balance. A lower HbA1c is not automatically safer if it causes recurrent severe lows. The ADA Standards of Care in Diabetes—2026 section on glycaemic goals and crises provides current professional guidance.
What ongoing follow-up covers
| Area | What is reviewed | Why it matters |
| Glucose | HbA1c, meter/CGM patterns, hypoglycaemia | Measures both effectiveness and safety |
| Kidneys | eGFR, urine albumin/creatinine, potassium | Early disease may have no symptoms |
| Cardiovascular risk | Blood pressure, lipids, smoking, vascular history | Diabetes risk care extends beyond glucose |
| Eyes | Dilated retinal examination and imaging when indicated | Retinopathy can be silent initially |
| Feet and nerves | Sensation, pulses, skin, deformity, shoes and wounds | Helps reduce ulcer and amputation risk |
| Medicine safety | Kidney/liver function, side effects, interactions, injection sites | Dose and drug suitability can change |
| Daily life | Food, activity, sleep, depression and diabetes distress | Sustainable self-care depends on these factors |
Follow-up is not one fixed interval. Reviews are usually more frequent after treatment changes, above-target readings, pregnancy or hypoglycaemia and may be spaced out when stable. A yearly “check-up” cannot replace daily management and regular local follow-up.
Diabetes technology
| Technology | Potential value | Limitation |
| Glucose meter | Measures capillary glucose at one moment | Technique, strip storage and hand cleanliness affect results |
| CGM | Shows trends, alarms and time-in-range data | Sensor lag or false alerts occur; finger checks are sometimes needed |
| Insulin pump | Delivers programmed basal and meal doses | Requires training, backup insulin and a rapid failure plan |
| Automated insulin delivery | Partly adjusts insulin using CGM data | Not fully automatic; meal and device management remain necessary |
| Telemonitoring / AI | Supports report summaries and remote contact | Does not replace clinical judgement, examination or emergency care |
Obtain device reports in a portable format. Before purchase, check sensor/set availability, technical support and prescription coverage in your home country. A claim that AI will “manage diabetes by itself” is unsafe.
Selecting a team and facility in Türkiye
Depending on need, care may involve endocrinology, internal medicine, a diabetes nurse/educator, dietitian, ophthalmology, nephrology, cardiology, neurology, a foot/wound team, dentistry, obstetrics and psychology. Confirm whether the facility and facilitator appear on the Türkiye Ministry of Health authorised provider lists.
Verify specialist credentials, laboratory standards, same-day urgent access, CGM/pump training, retinal and wound services, interpreting, privacy and the method of contact after you return. Treat guaranteed claims that stem cells, supplements, devices or surgery will permanently eliminate diabetes with caution.
International patient pathway
-
Prepare records: diagnosis year/type, 6–12 months of HbA1c and labs, medicines/doses, insulin ratios, pump/CGM reports, hypoglycaemia/crisis history and complications.
-
Pre-consultation: identify goals, missing tests, relevant specialists and what can realistically be done in Türkiye. A definite prescription or result should not be promised before examination.
-
Written programme and quotation: separate consultation, tests, imaging, education, technology, medicines, interpreting and follow-up.
-
In-person assessment: the clinician confirms classification and the current plan; alternatives, interactions and risks are explained.
-
Implementation and education: receive written dosing, low/high glucose, ketone, sick-day, foot-care and device instructions.
-
Return-home handover: arrange a clinical summary, monitoring schedule, prescriptions, laboratory requests and urgent contact.
The Clinicly Medical Tourism diabetes pathway explains which records may be requested; the Clinicly blog covers general travel preparation.
Travel checklist
-
Carry medicines, insulin, needles/strips/sensors and fast carbohydrate in hand luggage with prescriptions and a clinician letter.
-
Pack more supplies than the planned stay, a backup meter/battery and backup injected-insulin plan for pump failure.
-
Protect insulin from excessive heat, freezing and direct contact with ice; follow manufacturer instructions.
-
Plan time-zone dose changes with the clinician; do not make large adjustments alone.
-
Check airport-security and manufacturer guidance for CGM/pump devices.
-
Monitor more frequently when meals, activity or time zones change and inspect feet daily for blisters or injury.
The CDC travel guidance for diabetes emphasises hand-luggage access, extra supplies and protection from heat and cold.
What should an itemised quotation show?
| Item | Question to ask |
| Specialist assessment | How many endocrinology, dietitian and educator consultations? |
| Laboratory | Are HbA1c, kidney, urine albumin, lipid and indicated tests included? |
| Complication screening | Are retinal, foot, cardiac or kidney assessments indicated and included? |
| Technology | Are device, sensors/sets, setup, education and remote support separate? |
| Medicines | Are prescription, insulin/medicine cost and cold chain clearly separated? |
| Travel services | Are interpreting, transfer, accommodation and companion terms explicit? |
| Follow-up | How are reports, remote review, home-clinician handover and urgent contact handled? |
Diabetes care rarely ends with a single package. Calculate ongoing consumables, repeated tests and sustainable medicine costs at home. The lowest quotation is not safe if education, follow-up or complication screening is missing.
Frequently Asked Questions
1. Can diabetes be cured permanently?
Type 1 diabetes requires lifelong insulin. Type 2 diabetes may enter remission after substantial weight loss or surgery, but recurrence remains possible; it is not a guaranteed cure and monitoring continues.
2. Is the ideal HbA1c the same for everyone?
No. Age, pregnancy, duration, hypoglycaemia, cardiovascular/kidney disease and personal priorities alter the target.
3. Is one high HbA1c enough to diagnose diabetes?
Without unequivocal symptoms or crisis, the result is generally confirmed by a second laboratory measurement and possible HbA1c interference is considered.
4. May I stop insulin in type 1 diabetes if I am not eating?
No. Stopping basal insulin can cause ketoacidosis. Follow your sick-day plan for dose, fluids and ketones and contact your team.
5. Is a CGM or insulin pump suitable for everyone?
It can benefit many people, but need, training, skills, skin tolerance, cost and continuing access to supplies all matter.
6. When should my diabetes medicines change?
Above-target glucose, hypoglycaemia, adverse effects, kidney/heart status, pregnancy, weight priorities or access may trigger review. Do not change them yourself.
7. Does metabolic surgery permanently eliminate diabetes?
No. Selected people with type 2 diabetes may achieve remission, but recurrence, surgical risk and lifelong nutrition/micronutrient follow-up remain.
8. How often do I need follow-up?
The interval depends on treatment changes, glucose control, pregnancy and complications. The clinician individualises laboratory, eye, kidney and foot review.
9. Is flying with insulin safe?
It is generally manageable with correct storage, hand luggage, extra supply, documentation, time-zone planning and monitoring. Do not check insulin into hold baggage or freeze it.
10. Which documents should I take home?
Obtain the diagnosis/treatment summary, generic medicine names and doses, insulin ratios, laboratory and imaging results, pump/CGM settings, emergency plan and follow-up schedule.
Conclusion
Safe diabetes care in Türkiye is not a short “blood-sugar reduction package”. It links correct classification, individual targets, complication screening, self-management education and uninterrupted care after travel. Clinicly Medical Tourism can support record transfer, provider communication, interpreting and logistics; every prescription and treatment change must be made by the authorised clinician who evaluates the patient.
